FXN and Friedreich ataxia: Subsequently, RG2833 – the formulated form of 109 – has been taken forward to a phase I clinical trial showing increased levels of FXN mRNA and H3K9 acetylation in peripheral blood mononuclear cells from FRDA patients (Soragni et al., 2014).